A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma

MLA

William E. Carson, et al. “A Phase 2 Trial of Bevacizumab and High-Dose Interferon Alpha 2B in Metastatic Melanoma.” Journal of Immunotherapy, vol. 34, July 2011, pp. 509–15. EBSCOhost, https://doi.org/10.1097/cji.0b013e31821dcefd.

APA

William E. Carson, Cheryl Kefauver, Lai Wei, Kari Kendra, Cynthia Taylor, Valerie P. Grignol, Helen X. Chen, Amanda Kibler, Kiran V. Relekar, Thomas Olencki, & Michael Walker. (2011). A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma. Journal of Immunotherapy, 34, 509–515. https://doi.org/10.1097/cji.0b013e31821dcefd

Chicago

William E. Carson, Cheryl Kefauver, Lai Wei, Kari Kendra, Cynthia Taylor, Valerie P. Grignol, Helen X. Chen, et al. 2011. “A Phase 2 Trial of Bevacizumab and High-Dose Interferon Alpha 2B in Metastatic Melanoma.” Journal of Immunotherapy 34 (July): 509–15. doi:10.1097/cji.0b013e31821dcefd.